52 completed, 12 unknown, 11 recruiting, 6 not yet recruiting. 51 Phase 2, 30 Phase 3, 5 Not applicable, 2 Phase 1.
Follow Federation Francophone de Cancerologie Digestive: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalize (Signature Driven) Neoadjuvant Chemotherapy Trial for Patients With Resectable Borderline Pancreatic Ductal Adenocarcinoma. Nab paclitaxel / gemcitabine, mFOLFIRINOX - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 110 | 2026-06-01 | 2026-06-11 |
| A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC) mFOLFIRINOX (modified FOLFIRINOX) - Pancreas Adenocarcinoma (MSI-H), Pancreatic Cancer Resectable | Not applicable | Not yet recruiting | Institut Paoli-Calmettes | 367 | 2026-05-01 | 2026-05-18 |
| Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) FOLFIRI + Zimberelimab + Domvanalimab, FOLFIRI (standard of care) - Carcinoma, Neuroendocrine | Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 122 | 2026-04-01 | 2026-01-13 |
| Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer Fruquintinib - Metastatic Colorectal Cancer (CRC), Antineoplastic Agents, Immunological | Not applicable | Recruiting | Federation Francophone de Cancerologie Digestive | 300 | 2026-03-10 | 2026-05-26 |
| Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer Oxaliplatin intravenous, 5 FU bolus, Folinic acid - Metastatic Colorectal Carcinoma (mCRC) | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 74 | 2025-12-31 | 2025-09-08 |
| Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma trifluridine/tipiracil, fruquintinib - Metastatic Oesogastric Adenocarcinoma | Phase 3 | Recruiting | Federation Francophone de Cancerologie Digestive | 324 | 2025-12-15 | 2026-02-05 |
| PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma CISGEM + Rilvegostomig - Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 49 | 2025-10-30 | 2025-08-17 |
| Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1 - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | University Hospital, Clermont-Ferrand | 95 | 2025-10-07 | 2026-05-20 |
| 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab Administration of experimental treatment association (sotorasib, panitumumab 5FU) - Colorectal Carcinoma, KRAS G12C Mutation | Phase 2 | Not yet recruiting | Federation Francophone de Cancerologie Digestive | 300 | 2025-08-31 | 2025-08-15 |
| A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers Hepatocholangiocarcinoma, Fibrolamellar Carcinoma | Recruiting | Federation Francophone de Cancerologie Digestive | 150 | 2024-03-26 | 2025-08-05 | |
| Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA induction chemotherapy (mDCF), Concomitant chemotherapy (Capecitabin + Mitomycin-C), radiotherapy - Anal Cancer | Phase 3 | Recruiting | Federation Francophone de Cancerologie Digestive | 310 | 2024-02-26 | 2025-09-02 |
| Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM) Colorectal Cancer Metastatic, Microsatellite Instability-High Colorectal Cancer | Recruiting | Federation Francophone de Cancerologie Digestive | 600 | 2024-02-12 | 2025-10-06 | |
| Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy Ipilimumab Injection, Atezolizumab Injection, Bevacizumab - HCC - Hepatocellular Carcinoma, Metastatic Cancer | Phase 2 / Phase 3 | Completed | Federation Francophone de Cancerologie Digestive | 229 | 2023-03-09 | 2026-03-09 |
| Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer Encorafenib Oral Capsule + Cetuximab - Colorectal Cancer, BRAF V600E Mutation Positive | Phase 2 | Recruiting | Federation Francophone de Cancerologie Digestive | 30 | 2023-02-13 | 2025-09-02 |
| Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study DONEPEZIL, PLACEBO - Digestive Oncology, Supportive Care | Phase 2 | Completed | University Hospital, Clermont-Ferrand | 77 | 2022-06-02 | 2024-04-05 |
| Cohort of Tumors With POLE/D1 Mutation Tumors, POLE Exonuclease Domain Mutation | Unknown | Federation Francophone de Cancerologie Digestive | 100 | 2021-10-05 | 2024-07-08 | |
| Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate Capecitabine, Oxaliplatin, Bevacizumab - Colorectal Cancer Metastatic, High Immune Infiltrate | Phase 2 | Unknown | Federation Francophone de Cancerologie Digestive | 55 | 2021-04-06 | 2023-08-18 |
| Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer Atezolizumab, Therasphere, XELOX - Metastatic Colorectal Cancer, pMMR | Phase 2 | Unknown | Federation Francophone de Cancerologie Digestive | 52 | 2020-10-07 | 2023-08-18 |
| The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients Cancer, COVID | Completed | Federation Francophone de Cancerologie Digestive | 1523 | 2020-04-03 | 2022-04-04 | |
| Prospective Cohort of Patients With Hepatocellular Carcinoma in France Cancer of Liver, Hepatocellular Carcinoma | Recruiting | Centre Hospitalier Universitaire, Amiens | 5000 | 2019-09-26 | 2025-06-10 |
Showing 20 of 87. Sign in to see all of them.
Colorectal Neoplasms (32) · Colonic Neoplasms (15) · Rectal Neoplasms (11) · Neoplasms (10) · Neoplasm Metastasis (9) · Carcinoma, Hepatocellular (7) · Liver Neoplasms (7) · Pancreatic Neoplasms (7) · Esophageal Neoplasms (4) · Stomach Neoplasms (4) · Esophageal Squamous Cell Carcinoma (3) · Adenocarcinoma Of Esophagus (2) · Bile Duct Neoplasms (2) · Carcinoma, Neuroendocrine (2) · Carcinoma, Squamous Cell (2)
Fluorouracil (17) · Leucovorin (17) · Irinotecan (12) · Bevacizumab (11) · Gemcitabine (8) · Chemotherapy, Adjuvant (7) · Cetuximab (6) · Cisplatin (6) · Capecitabine (5) · Folfox protocol (5) · Oxaliplatin (5) · Radiotherapy (5) · IFL protocol (4) · Panitumumab (4) · HMPL-013 (3)
France (76) · Belgium (8) · Germany (8) · Martinique (4) · Netherlands (4) · Spain (4) · Italy (2) · Switzerland (2) · Austria (1) · Egypt (1) · Greece (1) · Israel (1) · Portugal (1) · Reunion (1) · Serbia (1)
Laurent Bedenne, MD (3) · Come Lepage, Pr (2) · Emmanuel Mitry, MD, PhD (2) · Jean-Francois Seitz, MD (2) · Julien Taieb, MD (2) · Julien Taieb, Pr (2) · Martina Schneider (2) · Pascal Hammel, MD, PhD (2) · Thomas Aparicio (2) · Thomas Aparicio, Pr (2) · Alfredo Carrato-Mena, MD (1)
PMID 24982463, PMID 42100890, PMID 16524973, PMID 17008704, PMID 17401004, PMID 17510208, PMID 17971585, PMID 18279058, PMID 18372134, PMID 18467316, PMID 19179549, PMID 19759186, PMID 20837948, PMID 20947887, PMID 21831734, PMID 23460711, PMID 23758655, PMID 24928083, PMID 25241229, PMID 25287828, PMID 25361220, PMID 26156156, PMID 26228970, PMID 26308942, PMID 26487578, PMID 26494856, PMID 26511668, PMID 28651158, PMID 29346040, PMID 29718089, PMID 30041614, PMID 30343254, PMID 31038408, PMID 31101691, PMID 31185328, PMID 31268130, PMID 31356278, PMID 31678771, PMID 32015513, PMID 32085892, PMID 32334940, PMID 32507854, PMID 32560632, PMID 32576496, PMID 32623182, PMID 32921581, PMID 33356421, PMID 33420951, PMID 33422006, PMID 33580623
2025 (3), 2005 (1), 2015 (1), 2017 (1), 2018 (1)